Last line therapy with sorafenib in colorectal cancer: A retrospective analysis

doi:10.3748/wjg.v22.i23.5400

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 23

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7572)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

818

WORD

363

HTML

2902

Figures (1-2)

230

Tables (1-4)

209

Sum=4522

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1127

Download

1923

Sum=3050

Jun 21, 2016 (publication date) through Sep 20, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jun 21, 2016; 22(23): 5400-5405
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5400

Table 3 Detailed treatment description of patients

Pt.	Comb. partner	6-wk		12-wk		PFS (d)	OS (d)
Pt.	Comb. partner	Response	% change	Response	% change	PFS (d)	OS (d)
1	5-FU	SD	-13%	SD	-7%	144	165
2	None	0	0	0	0	21	21
3	TU	SD	12%	0	0	79¹	163
4	5-FU	PD	35%	0	0	41	382
5	C	SD	-6%	PD	32%	149	302
6	TU	SD	-2%	0	0	32²	113
7	C	SD	-21%	SD	5%	137	188
8	C	SD	-4%	PD	24%	199	296
9	C	SD	3%	PD	32%	177	147
10	TU	SD	5%	SD	6%	188	447

¹Treatment stop due to bleeding complication;

²Treatment stop due to sorafenib allergy. TU: Tegafur Uracil; C: Capecitabine; SD: Stable disease; PD: Progressive disease; PFS: Progression free survival.

Citation: Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World J Gastroenterol 2016; 22(23): 5400-5405
URL: https://www.wjgnet.com/1007-9327/full/v22/i23/5400.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i23.5400